^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ADG106

    i
    Other names: ADG106, ADG 106, ADG-106
    Associations

    News

    Trials
    Company:
    Adagene
    Drug class:
    CD137 agonist
    Related drugs:
    Associations

    News

    Trials
    4ms
    ComPACT: Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=51, Recruiting, National University Hospital, Singapore | Phase classification: P1b --> P1/2 | Trial primary completion date: Dec 2025 --> Dec 2026
    Phase classification • Trial primary completion date
    |
    Keytruda (pembrolizumab) • ADG106
    6ms
    Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors. (PubMed, iScience)
    Elevated baseline memory T cells and PD-L1, activation of immune-related pathways, along with enhanced T cell proliferation and increased IFN-γ following treatment were observed in the PR patient. ADG106 in combination with toripalimab demonstrated a manageable safety profile but no efficacy conclusions could be drawn.
    P1/2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NCAM1 (Neural cell adhesion molecule 1) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Loqtorzi (toripalimab-tpzi) • ADG106
    over1year
    ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=58, Completed, Adagene Inc | Recruiting --> Completed | N=91 --> 58 | Trial completion date: Dec 2024 --> May 2024
    Trial completion • Enrollment change • Trial completion date • Combination therapy • Metastases
    |
    ADG106 • muzastotug (ADG126)
    over1year
    ADG116-1003: A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, Adagene Inc | Trial completion date: Aug 2024 --> Feb 2025 | Trial primary completion date: Jul 2024 --> Jan 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Loqtorzi (toripalimab-tpzi) • ADG106
    over1year
    A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=66, Active, not recruiting, National University Hospital, Singapore | Recruiting --> Active, not recruiting | Phase classification: P2 --> P1/2
    Enrollment closed • Phase classification • Combination therapy
    |
    paclitaxel • doxorubicin hydrochloride • cyclophosphamide • ADG106
    almost2years
    Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin's lymphoma. (PubMed, Cell Rep Med)
    Circulating biomarkers suggest target engagement by ADG106 and immune modulation of circulating T, B, and natural killer cells and cytokines interferon γ and interleukin-6, which may affect the probability of clinical efficacy. ADG106 has a manageable safety profile and preliminary anti-tumor efficacy in patients with advanced cancers (this study was registered at ClinicalTrials.gov: NCT03802955).
    P1 data • Preclinical • Journal • IO biomarker • Metastases
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    ADG106
    almost2years
    ADG116-1003: A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, Adagene Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Loqtorzi (toripalimab-tpzi) • ADG106
    over2years
    ComPACT: Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer (clinicaltrials.gov)
    P1b, N=51, Recruiting, National University Hospital, Singapore | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • ADG106
    over2years
    ADG106-1002: Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=62, Completed, Adagene (Suzhou) Limited | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL4 (Interleukin 4)
    |
    ADG106
    3years
    ADG106-1002: Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=62, Active, not recruiting, Adagene (Suzhou) Limited | Trial completion date: Aug 2022 --> Dec 2022
    Trial completion date • Metastases
    |
    IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL4 (Interleukin 4)
    |
    ADG106
    over3years
    ADG106-1002: Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=62, Active, not recruiting, Adagene (Suzhou) Limited | Trial completion date: Mar 2022 --> Aug 2022 | Trial primary completion date: Feb 2022 --> Nov 2021
    Trial completion date • Trial primary completion date
    |
    IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL4 (Interleukin 4)
    |
    ADG106
    almost4years
    ADG106-1002: Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=62, Active, not recruiting, Adagene (Suzhou) Limited | Trial primary completion date: Aug 2021 --> Feb 2022
    Trial primary completion date
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL4 (Interleukin 4)
    |
    ADG106